A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods

Trial Profile

A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Sotagliflozin (Primary) ; Canagliflozin
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Aug 2013 Planned number of patients changed from 36 to 24 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top